Table 1 Baseline characteristics of the intention-to-treat population
Characteristic | Socazolimab + TP (n = 32) | Placebo + TP (n = 32) | P |
|---|---|---|---|
Age, years | Â | Â | 0.388 |
 Median (range) | 61.0 (53–72) | 63.0 (47–74) |  |
Sex | Â | Â | 0.120 |
 Male | 23 (71.9) | 28 (87.5) |  |
 Female | 9 (28.1) | 4 (12.5) |  |
BMI, kg/m2 | 0.381 | ||
 Median (range) | 23.4 (13.7–30.6) | 23.5 (19.1–28.5) |  |
ECOG PS | Â | Â | 0.522 |
 0 | 25 (78.1) | 27 (84.4) |  |
 1 | 7 (21.9) | 5 (15.6) |  |
Tumor location | Â | Â | 0.454 |
 Proximal third | 9 (28.1) | 5(15.6) |  |
 Middle third | 18 (56.3) | 20 (62.5) |  |
 Distal third | 5 (15.6) | 7 (21.9) |  |
Clinical T stage | Â | Â | 1.000 |
 cT2 | 5 (15.6) | 4 (12.5) |  |
 cT3 | 26 (81.3) | 27 (84.4) |  |
 cT4a | 1 (3.1) | 1 (3.1) |  |
Clinical N stage | Â | Â | 0.514 |
 cN0 | 6 (18.8) | 7 (21.9) |  |
 cN1 | 17 (53.1) | 12 (37.5) |  |
 cN2 | 9 (28.1) | 12 (37.5) |  |
 cN3 | 0 (0.0) | 1 (3.1) |  |
Clinical stage | Â | Â | 0.756 |
 II | 11 (34.4) | 8 (25.0) |  |
 III | 19 (59.4) | 20 (62.5) |  |
 IVA | 1 (3.1) | 2 (6.3) |  |